A Pennsylvania representative has introduced a bill he says would pave the way for affordable generic insulin.

U.S. Representative Mike Kelly, R-Pa., has introduced what's called the Market Access for Generic Insulin Competition (MAGIC) Act of 2019.

According to Kelly, who is vice-chair of the Diabetes Caucus, the average annual cost of insulin for a type one diabetic has increased 600% over the last two decades.

"Millions of Americans are struggling to afford a drug they depend on to live, and many are dangerously resorting to rationing their prescriptions," Kelly said

Kelly says the MAGIC Act will make sure that federal law and regulatory barriers at the FDA no longer stand in the way of a competitive market for insulin.

"Historically, generic options are substantially cheaper and force down drug prices across the board. The same can and should be true of insulin," Kelly said.

The MAGIC Act will set a clear and permanent approval pathway at the Food and Drug Administration for generic insulin production via the abbreviated new drug application process, according to Kelly.

"Doing so will remedy a consequence of current law that permanently closes the door on generic insulin production after March 2020," Kelly said.